About: In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations
Creator	Wang, Wei Lu, Yong Liang, Bo Zhang, Ming Julander, Justin Lu, Y Wang, W Wei, Gang Zhang, M Zhu, Q Zhu, Qi Huang, S Baldwin, John Peng, H Yuan, X Baldwin, J Huang, Sammi Javer, Amin Julander, J Liang, ( Mendenhall, ( Mendenhall, Michelle Michail, H Michail, Hany Paul', St Peng, Haizhou Yuan, Xudong
Source	BioRxiv; Medline
abstract	To curb the spread of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, we characterize the virucidal activity of long-acting Povidone Iodine (PVP-I) compositions developed using an in-situ gel forming technology. The PVP-I gel forming nasal spray (IVIEW-1503) and PVP-I gel forming ophthalmic eye drop (IVIEW-1201) rapidly inactivated SARS-CoV-2, inhibiting the viral infection of VERO76 cells. No toxicity was observed for the PVP-I formulations. Significant inactivation was noted with preincubation of the virus with these PVP-I formulations at the lowest concentrations tested. It has been demonstrated that both PVP-I formulations can inactivate SARS-CoV-2 virus efficiently in both a dose-dependent and a time-dependent manner. These results suggest IVIEW-1503 and IVIEW-1201 could be potential agents to reduce or prevent the transmission of the virus through the nasal cavity and the eye, respectively. Further studies are needed to clinically evaluate these formulations in early-stage COVID-19 patients.
has issue date	2020-05-20(xsd:dateTime)
bibo:doi	10.1101/2020.05.18.103184
bibo:pmid	32511395
has license	biorxiv
sha1sum (hex)	efbcd8252634a8399ef9266caf8582f96c445489
schema:url	https://doi.org/10.1101/2020.05.18.103184
resource representing a document's title	In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations
has PubMed identifier	32511395
schema:publication	bioRxiv
resource representing a document's body	covid:efbcd8252634a8399ef9266caf8582f96c445489#body_text
is schema:about of	named entity 'in-situ' named entity 'eye drop' named entity 'dose-dependent' named entity 'COULD BE' named entity 'CONCENTRATIONS' named entity 'LONG-ACTING' named entity 'CURB' named entity 'PREVENT' named entity 'PATIENTS' named entity 'nasal cavity' named entity 'developed' named entity 'SARS-CoV-2' named entity 'observed' named entity 'manner' named entity 'virus' named entity 'Gel' named entity 'nasal spray' named entity 'PVP-I' named entity 'viral infection' named entity 'PVP-I' named entity 'IVIEW' named entity 'Povidone Iodine' named entity 'COVID-19 pandemic' named entity 'virucidal' named entity 'etiologic agent' named entity 'eye drop' named entity 'disinfectant' named entity 'EBV' named entity 'toxicity' named entity 'virucidal' named entity 'antiseptic' named entity 'PVP-I' named entity 'TMPRSS2' named entity 'PVP-I' named entity 'systemic disease' named entity 'iodine' named entity 'chloroquine' named entity 'SARS-CoV-2' named entity 'virus' named entity 'SARS' named entity 'S. aureus' named entity 'PVP-I' named entity 'COVID' named entity 'conjunctivitis' named entity 'PVP-I' named entity 'pathogenesis' named entity 'Group 3' named entity 'dysrhythmias' named entity 'prophylaxis' named entity 'ACE2' named entity 'nostril' named entity 'sinuses' named entity 'Middle East respiratory syndrome coronavirus' named entity 'SARS-CoV-2 virus' named entity 'topical medication' named entity 'RNA polymerase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software